NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

Avere Therapeutics highlighted AVR-001, a differentiated oral IL-23 receptor antagonist, with Phase 1b psoriasis data supporting potential for rapid development. The company positions the program as a convenient once-weekly oral therapy, which is a positive early signal but remains pre-Phase 2/3. Overall, the update is modestly supportive for sentiment rather than a near-term stock-moving catalyst.

Analysis

Avere Therapeutics highlighted AVR-001, a differentiated oral IL-23 receptor antagonist, with Phase 1b psoriasis data supporting potential for rapid development. The company positions the program as a convenient once-weekly oral therapy, which is a positive early signal but remains pre-Phase 2/3. Overall, the update is modestly supportive for sentiment rather than a near-term stock-moving catalyst.